127449-57-4

Upstream product

• 41467-27-0 3,3-bis(methylthio)-1-(p-tolyl)prop-2-en-1-one 
• 105-53-3 diethyl malonate 

Downstream Products

• 1512807-07-6 4-(methylthio)-2-oxo-N-phenyl-6-p-tolyl-2H-pyran-3-carboxamide 
• 1512808-08-0 C₂₁H₁₉NO₃S 
• 1512808-18-2 N-methyl-4-(methylthio)-2-oxo-6-p-tolyl-2H-pyran-3-carboxamide 
• 1512808-35-3 N-(2-hydroxyethyl)-4-(methylthio)-2-oxo-6-p-tolyl-2H-pyran-3-carboxamide 
• 1512808-45-5 methyl 2-(4-(methylthio)-2-oxo-6-p-tolyl-2H-pyran-3-carboxamido)acetate 
• 1512808-55-7 C₂₁H₁₉NO₃S 
• 1512807-51-0 4-(hydroxyamino)-2-oxo-N,6-di-p-tolyl-2H-pyran-3-carboxamide 
• 1512807-61-2 4-(hydroxyamino)-N-methyl-2-oxo-6-p-tolyl-2H-pyran-3-carboxamide 
• 1512807-75-8 4-(hydroxyamino)-N-(2-hydroxyethyl)-2-oxo-6-p-tolyl-2H-pyran-3-carboxamide 
• 1512807-88-3 methyl 2-(4-(hydroxyamino)-2-oxo-6-p-tolyl-2H-pyran-3-carboxamido)acetate 
• 1512807-26-9 4-(hydroxyamino)-2-oxo-N-phenyl-6-p-tolyl-2H-pyran-3-carboxamide 
• 1512807-97-4 N-benzyl-4-(hydroxyamino)-2-oxo-6-p-tolyl-2H-pyran-3-carboxamide 

Relevant academic research and scientific papers

Synthesis and anti-HCV determinant motif identification in pyranone carboxamide scaffold

Hepatitis C Virus exhibits high genetic diversity. The current treatment for genotype-1 with ～80% sustained virologic responses is a combination of pegylated interferon, ribavirin and boceprevir/telaprevir/simeprevir which is associated with several side

Synthesis and anti-HCV activity of 4-hydroxyamino α-pyranone carboxamide analogues

High genetic variability in hepatitis C virus (HCV), emergence of drug resistant viruses and side effects demand the requirement for development of new scaffolds to show an alternate mechanism. Herein, we report discovery of new scaffold I based on 4-hydr